PRME
Prime Medicine, Inc.
2.90$
-5.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -97.7% | +6,291.5% | -99.4% | +944.5% | -33.4% | -23.3% | +9.9% | -31.6% | +2.1% | +34.8% | – | |
| – | -71.5% | +5.5% | +17.0% | +1.3% | +10.2% | -1.0% | +9.6% | +2,260.0% | -95.7% | -1.1% | – | – | |
| – | – | – | – | – | +944.5% | -33.4% | -151.5% | – | – | -219.3% | – | – | |
| – | +1.2% | -8.9% | +14.0% | -6.3% | -15.5% | +18.9% | +2.0% | +6.3% | -21.1% | -1.7% | -2.1% | – | |
| – | +24.7% | -14.7% | +12.9% | +11.9% | -12.8% | +8.0% | -1.3% | -14.6% | +31.5% | +18.1% | -36.6% | – | |
| – | +32.2% | -30.0% | +16.9% | -2.2% | -14.8% | +16.0% | -2.3% | -78.7% | +341.2% | +0.4% | -10.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -76.0% | -200.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.